JP2012504122A5 - - Google Patents

Download PDF

Info

Publication number
JP2012504122A5
JP2012504122A5 JP2011529021A JP2011529021A JP2012504122A5 JP 2012504122 A5 JP2012504122 A5 JP 2012504122A5 JP 2011529021 A JP2011529021 A JP 2011529021A JP 2011529021 A JP2011529021 A JP 2011529021A JP 2012504122 A5 JP2012504122 A5 JP 2012504122A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
independently
aliphatic
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011529021A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012504122A (ja
JP5736314B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/005324 external-priority patent/WO2010036357A1/en
Publication of JP2012504122A publication Critical patent/JP2012504122A/ja
Publication of JP2012504122A5 publication Critical patent/JP2012504122A5/ja
Application granted granted Critical
Publication of JP5736314B2 publication Critical patent/JP5736314B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011529021A 2008-09-29 2009-09-25 1−アミノ−2−シクロブチルエチルボロン酸の誘導体 Active JP5736314B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19461408P 2008-09-29 2008-09-29
US61/194,614 2008-09-29
PCT/US2009/005324 WO2010036357A1 (en) 2008-09-29 2009-09-25 Derivatives of 1-amino-2-cyclobutylethylboronic acid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015085803A Division JP2015143264A (ja) 2008-09-29 2015-04-20 1−アミノ−2−シクロブチルエチルボロン酸の誘導体

Publications (3)

Publication Number Publication Date
JP2012504122A JP2012504122A (ja) 2012-02-16
JP2012504122A5 true JP2012504122A5 (cg-RX-API-DMAC10.html) 2012-11-15
JP5736314B2 JP5736314B2 (ja) 2015-06-17

Family

ID=41426361

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011529021A Active JP5736314B2 (ja) 2008-09-29 2009-09-25 1−アミノ−2−シクロブチルエチルボロン酸の誘導体
JP2015085803A Pending JP2015143264A (ja) 2008-09-29 2015-04-20 1−アミノ−2−シクロブチルエチルボロン酸の誘導体
JP2016199804A Pending JP2017025091A (ja) 2008-09-29 2016-10-11 1−アミノ−2−シクロブチルエチルボロン酸の誘導体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015085803A Pending JP2015143264A (ja) 2008-09-29 2015-04-20 1−アミノ−2−シクロブチルエチルボロン酸の誘導体
JP2016199804A Pending JP2017025091A (ja) 2008-09-29 2016-10-11 1−アミノ−2−シクロブチルエチルボロン酸の誘導体

Country Status (25)

Country Link
US (3) US8664200B2 (cg-RX-API-DMAC10.html)
EP (1) EP2346882B1 (cg-RX-API-DMAC10.html)
JP (3) JP5736314B2 (cg-RX-API-DMAC10.html)
KR (1) KR101739470B1 (cg-RX-API-DMAC10.html)
CN (2) CN103554143B (cg-RX-API-DMAC10.html)
AR (1) AR075090A1 (cg-RX-API-DMAC10.html)
AU (1) AU2009297113B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0919447B8 (cg-RX-API-DMAC10.html)
CA (1) CA2739375C (cg-RX-API-DMAC10.html)
CL (1) CL2011000653A1 (cg-RX-API-DMAC10.html)
CO (1) CO6362015A2 (cg-RX-API-DMAC10.html)
CR (2) CR20160475A (cg-RX-API-DMAC10.html)
DO (1) DOP2011000086A (cg-RX-API-DMAC10.html)
EA (1) EA030539B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP11011011A (cg-RX-API-DMAC10.html)
IL (1) IL211983A0 (cg-RX-API-DMAC10.html)
MA (1) MA32729B1 (cg-RX-API-DMAC10.html)
MX (1) MX2011003317A (cg-RX-API-DMAC10.html)
MY (1) MY166653A (cg-RX-API-DMAC10.html)
NZ (2) NZ606001A (cg-RX-API-DMAC10.html)
SG (1) SG194388A1 (cg-RX-API-DMAC10.html)
TW (2) TWI598352B (cg-RX-API-DMAC10.html)
UA (1) UA105503C2 (cg-RX-API-DMAC10.html)
WO (1) WO2010036357A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201203615B (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2623113B1 (en) 2005-11-09 2017-05-31 Onyx Therapeutics, Inc. Compound for enzyme inhibition
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
CA2701778C (en) 2007-10-04 2018-09-11 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
SI2318419T2 (sl) 2008-06-17 2025-10-30 Takeda Pharmaceutical Company Limited Spojine boronat estra in njihovi farmacevtski sestavki
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. ペプチドエポキシケトンを用いた併用療法
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
AU2011235227B2 (en) 2010-03-31 2016-09-08 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
EP2776586B1 (en) 2011-11-11 2018-03-07 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
CN104039328B (zh) 2011-11-11 2018-10-09 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记
SG10201605152SA (en) 2011-12-22 2016-08-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
WO2013112601A1 (en) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
MX2015006715A (es) * 2012-12-03 2015-08-14 Hoffmann La Roche Compuestos de acido triazolboronico sustituido.
US20160250238A1 (en) 2013-10-03 2016-09-01 Millennium Pharmaceuticals, Inc. Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis
ES2748434T3 (es) 2014-01-10 2020-03-16 Univ Cornell Dipéptidos como inhibidores de inmunoproteasomas humanos
UA121389C2 (uk) 2014-05-20 2020-05-25 Мілленніум Фармасьютікалз, Інк. Борвмісні інгібітори протеасом для застосування після первинної протиракової терапії
WO2016022955A1 (en) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
US11202817B2 (en) 2014-08-18 2021-12-21 Cornell University Dipeptidomimetics as inhibitors of human immunoproteasomes
US10640520B2 (en) * 2014-10-01 2020-05-05 Merck Patent Gmbh Boronic acid derivatives
EP3201208B1 (en) * 2014-10-01 2021-03-24 Merck Patent GmbH Boronic acid derivatives
AU2015327345B9 (en) * 2014-10-01 2020-06-18 Merck Patent Gmbh Boronic acid derivatives
EP3201207B1 (en) * 2014-10-01 2021-02-24 Merck Patent GmbH Boronic acid derivatives
EP4006012A1 (en) 2015-10-15 2022-06-01 Cornell University Proteasome inhibitors and uses thereof
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
JP7179721B2 (ja) 2016-06-21 2022-11-29 オリオン・オフサルモロジー・エルエルシー 複素環式プロリンアミド誘導体
WO2018160717A1 (en) 2017-02-28 2018-09-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
WO2019075252A1 (en) 2017-10-11 2019-04-18 Cornell University PEPTIDOMIMETIC INHIBITORS OF PROTEASOME
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
ES2960987T3 (es) 2019-04-12 2024-03-07 Riboscience Llc Derivados de heteroarilo bicíclicos como inhibidores de la ectonucleótido pirofosfatasa fosfodiesterasa 1

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ203706A (en) 1982-04-22 1986-03-14 Squibb & Sons Inc Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5159060A (en) 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) * 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
EP0583536B1 (en) 1992-08-14 1997-03-05 The Procter & Gamble Company Liquid detergents containing an alpha-amino boronic acid
US5935944A (en) 1993-09-10 1999-08-10 Neutron Technology Corporation Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA)
US5492900A (en) 1993-09-10 1996-02-20 Neutron Technology Corporation Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA)
US6060462A (en) 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US6271199B2 (en) 1997-02-15 2001-08-07 Millennium Pharmaceuticals, Inc. Treatment of infarcts
AU9580098A (en) 1997-09-25 1999-04-12 Millennium Pharmaceuticals, Inc. Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-(k)b via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases
CA2314259A1 (en) 1997-12-16 1999-06-24 Robert Siman Multicatalytic protease inhibitors for use as anti-tumor agents
US6169076B1 (en) 1999-03-31 2001-01-02 Glcosyn Pharmaceuticals, Inc. P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols
WO2001002424A2 (en) 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
CA2435146C (en) 2001-01-25 2011-03-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
EP1399468B1 (en) 2001-05-30 2006-02-15 Novartis AG 2-((n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl)-amino)-alkylboronic acid derivatives
WO2003033507A1 (en) 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Benzylmalonic acid derivatives and proteasome inhibitors contaiing the same
EP1463719A2 (en) 2002-01-08 2004-10-06 Eisai Co., Ltd Eponemycin and epoxomicin analogs and uses thereof
AU2003223930A1 (en) 2002-06-14 2003-12-31 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
US20060084592A1 (en) 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
TWI345465B (en) * 2003-08-14 2011-07-21 Cephalon Inc Proteasome inhibitors and methods of using the same
GB0405267D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
ES2899606T3 (es) 2004-03-30 2022-03-14 Millennium Pharm Inc Síntesis de compuestos de ésteres y ácidos borónicos
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
CN101247799B (zh) 2005-07-05 2013-03-27 塔夫茨大学信托人 成纤维细胞活化蛋白α的抑制剂
WO2007089618A2 (en) 2006-01-27 2007-08-09 Phenomix Corporation Hepatitis c serine protease inhibitors and uses therefor
WO2009006473A2 (en) 2007-07-05 2009-01-08 Trustees Of Tufts College Pro-soft polypeptide proteasome inhibitors, and methods of use thereof
KR20140042933A (ko) 2007-08-06 2014-04-07 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아좀 억제제
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
SI2318419T2 (sl) 2008-06-17 2025-10-30 Takeda Pharmaceutical Company Limited Spojine boronat estra in njihovi farmacevtski sestavki
AU2011235227B2 (en) 2010-03-31 2016-09-08 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid

Similar Documents

Publication Publication Date Title
RU2012146194A (ru) Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
JP2015511217A5 (cg-RX-API-DMAC10.html)
RU2012146819A (ru) Ингибиторы аргиназы и их терапевтические применения
JP2017505314A5 (cg-RX-API-DMAC10.html)
TW201039865A (en) Lyophilized preparations of proteasome inhibitors
JPH07108855B2 (ja) 循環器治療薬として有用な酸化窒素―第一級アミン安定化コンプレックス
JP2013544261A5 (cg-RX-API-DMAC10.html)
JP2013526501A5 (cg-RX-API-DMAC10.html)
JP2009519222A5 (cg-RX-API-DMAC10.html)
JP2014518882A5 (cg-RX-API-DMAC10.html)
RU2012146101A (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
JP2017531624A5 (cg-RX-API-DMAC10.html)
JP2015501833A5 (cg-RX-API-DMAC10.html)
AR075090A1 (es) Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
JP2008533191A5 (cg-RX-API-DMAC10.html)
JP2014508814A (ja) リチウム組成物
JP2022081630A (ja) ベンゾアゼピン化合物含有凍結乾燥組成物
TR201908746T4 (tr) Bir aktif içerik maddesi olarak tetrazol türevini içeren gelişmiş çözünürlüklü katı dispersiyonu.
JP5086497B1 (ja) ボロン酸化合物を含有したブロック共重合体を含む医薬組成物
RU2014133390A (ru) Производные изохинолина и нафтиридина
RU2013136861A (ru) Новое производное индола или индазола или его соль
RU2011142154A (ru) Производные фосфлокуназола, их синтез и применение в препаратах длительного действия
US20140072604A1 (en) Block Copolymer For Intraperitoneal Administration Containing Anti-Cancer Agent, Micelle Preparation Thereof, And Cancer Therapeutic Agent Comprising The Micelle Preparation As Active Ingredient
RU2015113959A (ru) Индолины
JP2018024648A (ja) ボルテゾミブを含有する医薬製剤の製造方法